Why Diabetes Changes the Research Question
It is tempting to treat all obesity trials as interchangeable. They are not. A population with type 2 diabetes can have different baseline characteristics, background interventions and metabolic outcomes than a population without that diagnosis. The clinical program for eloralintide therefore deserves a closer look by population rather than by headline percentage.
A Registered Phase 3 Population
ClinicalTrials.gov lists NCT07282600, acronym ENLIGHTEN-2, as a Phase 3, randomized, double-blind, placebo-controlled study of once-weekly eloralintide in adults with obesity or overweight and type 2 diabetes. [1] As of October 13, 2026 the record shows a status of recruiting, a planned enrollment of 1,035 participants, a start date of December 15, 2025 and an estimated primary completion in January 2028. The registered primary outcome is percent change in body weight from baseline to Week 64.
A record like this tells readers what is under investigation. It does not indicate whether the trial will meet its endpoints or what the safety findings will be.
A Second Phase 3 Study in a Mixed Population
A separate Phase 3 registration, NCT07392190 (ENLIGHTEN-6), covers adults with persistent obesity or overweight who are being treated with a weekly incretin, with and without type 2 diabetes. [4] As of October 13, 2026 it is recruiting, with a planned enrollment of 900 participants and a registered primary outcome of percent change in body weight. Because its population mixes people with and without diabetes, it should not be read as a diabetes-only study.
Related Research With Macupatide
Another registry entry, NCT07215559, is a Phase 2 study of macupatide and eloralintide, alone or in combination, in adults with obesity or overweight and type 2 diabetes. [2] As of October 13, 2026 it is active but no longer recruiting, with a planned enrollment of 200 participants, a start date of October 16, 2025 and an estimated primary completion in March 2027. This is a separate study, not an interchangeable arm of NCT07282600. Its design and outcomes need to be interpreted as registered for that study alone.
An investigational combination can raise questions about complementary metabolic signaling. But the existence of that research does not establish a benefit from the combination.
Diabetes Outcomes and Body Weight Are Different Measures
Research involving type 2 diabetes can consider glycemic outcomes alongside body weight. Hemoglobin A1c reflects average glycemic exposure over time; it is not the same measure as percentage body-weight change. In the ENLIGHTEN-2 record, body weight is the registered primary outcome and hemoglobin A1c is listed among the secondary outcomes. Even when both are reported in one study, the endpoints require separate interpretation.
Before reporting any future finding, look for the primary endpoint, study duration, comparator and statistical assumptions. A sponsor announcement and a complete peer-reviewed article should also be labeled according to their actual source status.
Keep the Programs Apart
The earlier peer-reviewed standalone eloralintide Phase 2 study excluded people with type 2 diabetes. [3] Its outcomes should not be read as though they came from the diabetes-specific registered programs. This is a straightforward but important source of confusion in online discussion.
The proper question is not what the largest percentage on a slide looks like. It is what a defined study shows in its own participants under its own protocol.
The Bottom Line
The diabetes research program is about generating evidence in a specific population. Registration establishes the investigation. Later results, once posted and scrutinized, will determine what can actually be said about its outcomes.
FAQ
Does a type 2 diabetes trial mean an investigational medicine has been authorized for diabetes?
No. Registration is a research milestone, not a regulatory decision.
Is the Phase 3 study the same as the macupatide combination trial?
No. They have different registry identifiers, phases and study designs. [1][2]
Can the earlier Phase 2 percentages be transferred to the diabetes program?
No. The earlier trial enrolled a different population. [3]
Why are glycemic and body-weight endpoints different?
They measure different outcomes and can require different statistical analyses.
Further reading: Eloralintide clinical trials, Clinical development and Eloralintide vs tirzepatide
Editorial note
This article discusses investigational drug research for educational purposes. It does not provide medical advice, treatment recommendations, or instructions for obtaining or administering experimental compounds. Clinical findings should be interpreted within their original study populations and methodological limitations.